{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:28:13Z","timestamp":1790368093653,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["chestpulmonary.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST Pulmonary"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.chpulm.2024.100124","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T21:43:57Z","timestamp":1732052637000},"page":"100124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Study Design and Rationale for the TETON-PPF Phase 3, Randomized, Controlled Clinical Trial of Inhaled Treprostinil in the Treatment of Progressive Pulmonary Fibrosis"],"prefix":"10.1016","volume":"3","author":[{"given":"Steven D.","family":"Nathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2051-7774","authenticated-orcid":false,"given":"Peter","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5641-4101","authenticated-orcid":false,"given":"CQ","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0545-6432","authenticated-orcid":false,"given":"Natalie","family":"Breytenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-055X","authenticated-orcid":false,"given":"Heidi","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1218-5435","authenticated-orcid":false,"given":"Leigh","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7686-0291","authenticated-orcid":false,"given":"Kevin R.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"150","key":"10.1016\/j.chpulm.2024.100124_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.chpulm.2024.100124_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur Resp J"},{"issue":"5","key":"10.1016\/j.chpulm.2024.100124_bib3","doi-asserted-by":"crossref","first-page":"1800692","DOI":"10.1183\/13993003.00692-2018","article-title":"What\u2019s in a name? That which we call IPF, by any other name would act the same","volume":"51","author":"Wells","year":"2018","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.chpulm.2024.100124_bib4","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"150","key":"10.1016\/j.chpulm.2024.100124_bib5","article-title":"Role of imaging in progressive-fibrosing interstitial lung diseases","volume":"27","author":"Walsh","year":"2018","journal-title":"Eur Resp Rev"},{"issue":"5","key":"10.1016\/j.chpulm.2024.100124_bib6","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1513\/AnnalsATS.201807-443OC","article-title":"Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases","volume":"16","author":"Adegunsoye","year":"2019","journal-title":"Ann Am Thorac Soc"},{"issue":"18","key":"10.1016\/j.chpulm.2024.100124_bib7","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"New Engl J Med"},{"issue":"153","key":"10.1016\/j.chpulm.2024.100124_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0109-2019","article-title":"Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"18","key":"10.1016\/j.chpulm.2024.100124_bib9","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.chpulm.2024.100124_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chpulm.2024.100124_bib11","series-title":"United Therapeutics Corp","article-title":"Tyvaso (treprostinil) inhalation solution, for oral inhalation use. Prescribing information","year":"2022"},{"issue":"1","key":"10.1016\/j.chpulm.2024.100124_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (Ip) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.chpulm.2024.100124_bib13","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1007\/s12325-022-02229-8","article-title":"The antifibrotic effects of inhaled treprostinil: an emerging option for ILD","volume":"39","author":"Kolb","year":"2022","journal-title":"Adv Ther"},{"issue":"S59","key":"10.1016\/j.chpulm.2024.100124_bib14","first-page":"3893","article-title":"Treprostinil effectively inhibits PDGF and TGF-beta1 induced extracellular matrix composition by IPF fibroblasts","volume":"46","author":"Lambers","year":"2015","journal-title":"Eur Resp J"},{"issue":"669227","key":"10.1016\/j.chpulm.2024.100124_bib15","article-title":"Inhibition of the proliferation of human lung fibroblasts by prostacyclin receptor agonists is linked to a sustained cAMP signal in the nucleus","volume":"12","author":"Roberts","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.chpulm.2024.100124_bib16","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41598-018-19294-1","article-title":"Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation","volume":"8","author":"Lambers","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.chpulm.2024.100124_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019881954","article-title":"Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice","volume":"9","author":"Nikitopoulou","year":"2019","journal-title":"Pulm Circ"},{"issue":"5","key":"10.1016\/j.chpulm.2024.100124_bib18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1165\/rcmb.2018-0142OC","article-title":"The antifibrotic activity of prostacyclin receptor agonism is mediated through inhibition of YAP\/TAZ","volume":"60","author":"Amajkovicov","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.chpulm.2024.100124_bib29","series-title":"NCT02630316. ClinicalTrials.gov. United Therapeutics; 2017","article-title":"United Therapeutics. Safety and efficacy of inhaled treprostinil in adult PH with ILD including CPFE","year":"2022"},{"issue":"11","key":"10.1016\/j.chpulm.2024.100124_bib19","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chpulm.2024.100124_bib30","series-title":"NCT05943535. ClinicalTrials.gov. United Therapeutics; 2023","article-title":"United Therapeutics. Study of the efficacy and safety of inhaled treprostinil in subjects with progressive pulmonary fibrosis (TETON-PPF)","year":"2025"},{"key":"10.1016\/j.chpulm.2024.100124_bib20","series-title":"Long-term effects of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease: the INCREASE study open-label extension","author":"Waxman","year":"2022"},{"key":"10.1016\/j.chpulm.2024.100124_bib31","series-title":"NCT04708782. ClinicalTrials.gov. United Therapeutics; 2021","article-title":"United Therapeutics. Study of efficacy and safety of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis (TETON)","year":"2025"},{"key":"10.1016\/j.chpulm.2024.100124_bib32","series-title":"NCT05255991. ClinicalTrials.gov. United Therapeutics; 2022","article-title":"United Therapeutics. Multinational study of efficacy and safety of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis (TETON-2)","year":"2025"},{"issue":"1","key":"10.1016\/j.chpulm.2024.100124_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001310","article-title":"Study design and rationale for the TETON phase 3, randomized, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Resp Res"},{"key":"10.1016\/j.chpulm.2024.100124_bib22","series-title":"Boehringer Ingelheim Pharmaceuticals Inc.","article-title":"Ofev (nintedanib capsules), for oral use. Prescribing information","year":"2024"},{"issue":"2","key":"10.1016\/j.chpulm.2024.100124_bib23","doi-asserted-by":"crossref","first-page":"00423","DOI":"10.1183\/23120541.00423-2022","article-title":"Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study","volume":"9","author":"Raman","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.chpulm.2024.100124_bib24","series-title":"Applied Pharmacology","first-page":"17","article-title":"Pharmacokinetics","author":"Bardal","year":"2011"},{"key":"10.1016\/j.chpulm.2024.100124_bib33","series-title":"NCT02999178. ClinicalTrials.gov. Boehringer Ingelheim; 2017","article-title":"Boehringer Ingelheim. Efficacy and safety of nintedanib in patients with progressive fibrosing interstitial lung disease (PF-ILD) (INBUILD)","year":"2020"},{"issue":"1","key":"10.1016\/j.chpulm.2024.100124_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1164\/rccm.202201-0124OC","article-title":"Validation of proposed criteria for progressive pulmonary fibrosis","volume":"207","author":"Pugashetti","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"container-title":["CHEST Pulmonary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949789224000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949789224000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T09:27:55Z","timestamp":1751016475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949789224000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2949789224000904"],"URL":"https:\/\/doi.org\/10.1016\/j.chpulm.2024.100124","relation":{},"ISSN":["2949-7892"],"issn-type":[{"value":"2949-7892","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study Design and Rationale for the TETON-PPF Phase 3, Randomized, Controlled Clinical Trial of Inhaled Treprostinil in the Treatment of Progressive Pulmonary Fibrosis","name":"articletitle","label":"Article Title"},{"value":"CHEST Pulmonary","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chpulm.2024.100124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100124"}}